Open Access Highly Accessed Email this article to a friend

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

Cheng Liao*, Jonathan Hsu, Yong Kim, Dong-Qing Hu, Daigen Xu, Jun Zhang, Achal Pashine, John Menke, Toni Whittard, Natasha Romero, Theresa Truitt, Michelle Slade, Christine Lukacs, Johannes Hermann, Mingyan Zhou, Matthew Lucas, Satwant Narula, Julie DeMartino and Seng-Lai Tan

Arthritis Research & Therapy 2013, 15:R146  doi:10.1186/ar4329

Fields marked * are required

Multiple email addresses should be separated with commas or semicolons.
How can I ensure that I receive Arthritis Research & Therapy's emails?